Molecular Imaging and Biology

, Volume 11, Issue 5, pp 296–302

Correlating Metabolic Activity with Cellular Proliferation in Follicular Lymphomas

  • Bingfeng Tang
  • Jozef Malysz
  • Vonda Douglas-Nikitin
  • Richard Zekman
  • Regina Heather Wong
  • Ishmael Jaiyesimi
  • Ching-yee Oliver Wong
Rapid Communication

Abstract

Purpose

The aim of this study was to correlate metabolic behavior of follicular lymphoma with proliferative index (Ki67).

Materials and Methods

Pre-treatment 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography–computed tomography scans of 23 patients with pathologic diagnosis of follicular lymphoma were retrospectively analyzed together with Ki67. The maximal standardized uptake value (SUV) was measured and corrected to glucose level of 100 mg/dl over the biopsy region (BxSUV100) and at the highest tumor activity of the body (BmSUV100).

Results

BxSUV100 was significantly correlated with Ki67 (p = 0.037). There was an increasing trend of metabolic activity across the pathologic grades of follicular lymphomas. BmSUV100 and BxSUV100 were also significantly different (p < 0.0005), suggesting potential pitfalls of sampling error by histology.

Conclusion

The increasing trend of metabolic activity across follicular lymphoma grades correlates with cellular proliferation. The metabolic information from positron emission tomography–computed tomography may offer another useful parameter in the management of follicular lymphomas.

Key words

Follicular lymphoma PET–CT Bone marrow 

References

  1. 1.
    Kumar R, Maillard I, Schuster DJ et al (2004) Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin’s and non-Hodgkin’s lymphomas. Radiol Clin North Am 42:1083–1100PubMedCrossRefGoogle Scholar
  2. 2.
    Burton C, Ell P, Linch D (2004) The role of PET imaging in lymphoma. Br J Haematol 126:772–784PubMedCrossRefGoogle Scholar
  3. 3.
    The Non-Hodgkin’s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 89:3909–3918Google Scholar
  4. 4.
    Lu P (2005) Staging and classification of lymphoma. Semin Nucl Med 35:160–164PubMedCrossRefGoogle Scholar
  5. 5.
    Gerdes J, Schwab U, Lemke H et al (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13–20PubMedCrossRefGoogle Scholar
  6. 6.
    Bryant RJ, Banks PM, O’Malley DP (2006) Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology 48:505–515PubMedCrossRefGoogle Scholar
  7. 7.
    Wirth A, Foo M, Seymour JF et al (2008) Impact of 18F-fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 71:213–219PubMedGoogle Scholar
  8. 8.
    Karam M, Novak L, Cyriac J et al (2006) Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107:175–183PubMedCrossRefGoogle Scholar
  9. 9.
    Wong CYO, Thie J, Parling-Lynch KJ et al (2007) Investigating the existence of quantum metabolic values in non-Hodgkin’s lymphoma by F-18 FDG. Mol Imaging Biol 9(1):43–49PubMedCrossRefGoogle Scholar
  10. 10.
    Wong CYO, Thie J, Parling-Lynch KJ, Zakalik D, Margolis JH, Qing F, Fink-Bennett D, Nagle C (2005) Glucose-normalized standard uptake value (SUV) from F-18 FDG PET in classifying lymphomas. J Nucl Med 46(10):1659–1663PubMedGoogle Scholar
  11. 11.
    Wohrer S, Jaeger U, Kletter K et al (2006) 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Annals of Oncol 17:780–784CrossRefGoogle Scholar
  12. 12.
    Schoder H, Noy A, Gonen M et al (2005) Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23:4643–4651PubMedCrossRefGoogle Scholar
  13. 13.
    Allen-Auerbach M, Quon A, Weber WA et al (2004) Comparison between 2-deoxy-2-[(18)F]Fluoro-D-glucose positron-emission tomography and positron-emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 6:411–416PubMedCrossRefGoogle Scholar

Copyright information

© Academy of Molecular Imaging 2009

Authors and Affiliations

  • Bingfeng Tang
    • 1
  • Jozef Malysz
    • 2
  • Vonda Douglas-Nikitin
    • 2
  • Richard Zekman
    • 3
  • Regina Heather Wong
    • 1
  • Ishmael Jaiyesimi
    • 3
  • Ching-yee Oliver Wong
    • 1
  1. 1.Positron Diagnostic Center and Medical Cyclotron, Department of Nuclear MedicineWilliam Beaumont HospitalRoyal OakUSA
  2. 2.Department of PathologyWilliam Beaumont HospitalRoyal OakUSA
  3. 3.Department of Medical OncologyWilliam Beaumont HospitalRoyal OakUSA

Personalised recommendations